{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,7]],"date-time":"2024-12-07T05:13:02Z","timestamp":1733548382109,"version":"3.30.1"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,6]]},"DOI":"10.7759\/cureus.75217","type":"journal-article","created":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T14:30:09Z","timestamp":1733495409000},"source":"Crossref","is-referenced-by-count":0,"title":["Remarkable Response to Dabrafenib and Trametinib in a V-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF) V600E-Mutated Lung Adenocarcinoma Patient With Poor Performance Status and Respiratory Failure: A Case Report"],"prefix":"10.7759","author":[{"given":"Satoshi","family":"Anai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohei","family":"Isa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rin","family":"Chibana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiho","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00762","article-title":"Therapy for stage IV non-small cell lung cancer with driver alterations: ASCO living guideline, version 2024.1","volume":"42","author":"Owen DH","year":"2024","unstructured":"Owen DH, Ismaila N, Freeman-Daily J, Roof L, Singh N, Velazquez AI, Leighl NB. Therapy for stage IV non-small cell lung cancer with driver alterations: ASCO living guideline, version 2024.1. J Clin Oncol. 2024, 42:e44-59. 10.1200\/JCO.24.00762","journal-title":"J Clin Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.7658","article-title":"First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy","volume":"27","author":"Inoue A","year":"2009","unstructured":"Inoue A, Kobayashi K, Usui K, et al.. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol. 2009, 27:1394-400. 10.1200\/JCO.2008.18.7658","journal-title":"J Clin Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.02.012","article-title":"Alectinib for patients with ALK rearrangement-positive non-small cell lung cancer and a poor performance status (Lung Oncology Group in Kyushu\u00a01401)","volume":"12","author":"Iwama E","year":"2017","unstructured":"Iwama E, Goto Y, Murakami H, et al.. Alectinib for patients with ALK rearrangement-positive non-small cell lung cancer and a poor performance status (Lung Oncology Group in Kyushu\u00a01401). J Thorac Oncol. 2017, 12:1161-6. 10.1016\/j.jtho.2017.02.012","journal-title":"J Thorac Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s13691-022-00556-9","article-title":"Dabrafenib plus trametinib treatment for a patient with BRAF V600E-mutated large-cell lung carcinoma and a poor performance status","volume":"11","author":"Nakajima Y","year":"2022","unstructured":"Nakajima Y, Nishijima Y, Niida A, et al.. Dabrafenib plus trametinib treatment for a patient with BRAF V600E-mutated large-cell lung carcinoma and a poor performance status. Int Cancer Conf J. 2022, 11:266-9. 10.1007\/s13691-022-00556-9","journal-title":"Int Cancer Conf J"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200206000-00010","article-title":"TTF-1 expression in pulmonary adenocarcinomas","volume":"26","author":"Yatabe Y","year":"2002","unstructured":"Yatabe Y, Mitsudomi T, Takahashi T. TTF-1 expression in pulmonary adenocarcinomas. Am J Surg Pathol. 2002, 26:767-73. 10.1097\/00000478-200206000-00010","journal-title":"Am J Surg Pathol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2022.05.014","article-title":"Targeting BRAF-mutant non-small cell lung cancer: current status and future directions","volume":"169","author":"Riudavets M","year":"2022","unstructured":"Riudavets M, Cascetta P, Planchard D. Targeting BRAF-mutant non-small cell lung cancer: current status and future directions. Lung Cancer. 2022, 169:102-14. 10.1016\/j.lungcan.2022.05.014","journal-title":"Lung Cancer"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00552-7","article-title":"BRAF(V600E)-mutant metastatic NSCLC: disease overview and treatment landscape","volume":"8","author":"Planchard D","year":"2024","unstructured":"Planchard D, Sanborn RE, Negrao MV, Vaishnavi A, Smit EF. BRAF(V600E)-mutant metastatic NSCLC: disease overview and treatment landscape. NPJ Precis Oncol. 2024, 8:90. 10.1038\/s41698-024-00552-7","journal-title":"NPJ Precis Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30679-4","article-title":"Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial","volume":"18","author":"Planchard D","year":"2017","unstructured":"Planchard D, Smit EF, Groen HJ, et al.. Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol. 2017, 18:1307-16. 10.1016\/S1470-2045(17)30679-4","journal-title":"Lancet Oncol"},{"key":"ref9","article-title":"Alectinib was effective even in a poor performance status patient after craniotomy for cerebellar herniation [Article in Japanese]","volume":"9","author":"Tomoaki Takao","year":"2020","unstructured":"Tomoaki Takao, Satoshi Anai, Junko Hisasue, et al.. Alectinib was effective even in a poor performance status patient after craniotomy for cerebellar herniation [Article in Japanese]. Kokyuki Gakkai Zasshi. 2020, 9:65-70.","journal-title":"Kokyuki Gakkai Zasshi"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.107190","article-title":"Clinical application of the AMOY 9-in-1 panel to lung cancer patients","volume":"179","author":"Kunimasa K","year":"2023","unstructured":"Kunimasa K, Matsumoto S, Kawamura T, et al.. Clinical application of the AMOY 9-in-1 panel to lung cancer patients. Lung Cancer. 2023, 179:107190. 10.1016\/j.lungcan.2023.107190","journal-title":"Lung Cancer"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/321865-remarkable-response-to-dabrafenib-and-trametinib-in-a-v-raf-murine-sarcoma-viral-oncogene-homolog-b-braf-v600e-mutated-lung-adenocarcinoma-patient-with-poor-performance-status-and-respiratory-failure-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T14:30:10Z","timestamp":1733495410000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/321865-remarkable-response-to-dabrafenib-and-trametinib-in-a-v-raf-murine-sarcoma-viral-oncogene-homolog-b-braf-v600e-mutated-lung-adenocarcinoma-patient-with-poor-performance-status-and-respiratory-failure-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,6]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.75217","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,6]]}}}